J M SMUCKER Co — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that J M SMUCKER Co filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $3.38B | Jun 18, 2025 |
| FY2025 | Apr 30, 2024 | $3.12B | Jun 18, 2025 |
| FY2025 | Apr 30, 2023 | $2.80B | Jun 18, 2025 |
| FY2024 | Apr 30, 2022 | $2.70B | Jun 18, 2024 |
| FY2023 | Apr 30, 2021 | $3.14B | Jun 20, 2023 |
| FY2020 | Apr 30, 2020 | $788.40M | Jun 19, 2020 |
| FY2020 | Jan 31, 2020 | $760.00M | Jun 19, 2020 |
| FY2020 | Oct 31, 2019 | $754.00M | Jun 19, 2020 |
| FY2020 | Jul 31, 2019 | $699.60M | Jun 19, 2020 |
| FY2020 | Apr 30, 2019 | $692.40M | Jun 19, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | ($1.23B) | Jun 18, 2025 |
| FY2025 | Apr 30, 2024 | $744.00M | Jun 18, 2025 |
| FY2025 | Apr 30, 2023 | ($91.30M) | Jun 18, 2025 |
| FY2024 | Apr 30, 2022 | $631.70M | Jun 18, 2024 |
| FY2023 | Apr 30, 2021 | $876.30M | Jun 20, 2023 |
| FY2020 | Apr 30, 2020 | $226.30M | Jun 19, 2020 |
| FY2020 | Jan 31, 2020 | $187.40M | Jun 19, 2020 |
| FY2020 | Oct 31, 2019 | $211.20M | Jun 19, 2020 |
| FY2020 | Jul 31, 2019 | $154.60M | Jun 19, 2020 |
| FY2020 | Apr 30, 2019 | $71.50M | Jun 19, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | ($673.90M) | Jun 18, 2025 |
| FY2025 | Apr 30, 2024 | $1.31B | Jun 18, 2025 |
| FY2025 | Apr 30, 2023 | $157.50M | Jun 18, 2025 |
| FY2024 | Apr 30, 2022 | $1.02B | Jun 18, 2024 |
| FY2023 | Apr 30, 2021 | $1.39B | Jun 20, 2023 |
| FY2022 | Apr 30, 2020 | $1.22B | Jun 16, 2022 |
| FY2021 | Apr 30, 2019 | $928.60M | Jun 17, 2021 |
| FY2020 | Apr 30, 2018 | $1.04B | Jun 19, 2020 |
| FY2019 | Apr 30, 2017 | $1.04B | Jun 17, 2019 |
| FY2018 | Apr 30, 2016 | $1.15B | Jun 18, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Apr 30, 2017 | $58.10M | Jun 19, 2017 |
| FY2017 | Apr 30, 2016 | $58.80M | Jun 19, 2017 |
| FY2017 | Apr 30, 2015 | $32.50M | Jun 19, 2017 |
| FY2016 | Apr 30, 2014 | $24.30M | Jun 21, 2016 |
| FY2015 | Apr 30, 2013 | $24.70M | Jun 25, 2015 |
| FY2014 | Apr 30, 2012 | $21.90M | Jun 23, 2014 |
| FY2013 | Apr 30, 2011 | $21.00M | Jun 21, 2013 |
| FY2012 | Apr 30, 2010 | $20.96M | Jun 25, 2012 |
| FY2011 | Apr 30, 2009 | $14.50M | Jun 28, 2011 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $1.53B | Jun 18, 2025 |
| FY2025 | Apr 30, 2024 | $1.45B | Jun 18, 2025 |
| FY2025 | Apr 30, 2023 | $1.46B | Jun 18, 2025 |
| FY2024 | Apr 30, 2022 | $1.36B | Jun 18, 2024 |
| FY2023 | Apr 30, 2021 | $1.52B | Jun 20, 2023 |
| FY2022 | Apr 30, 2020 | $1.47B | Jun 16, 2022 |
| FY2021 | Apr 30, 2019 | $1.51B | Jun 17, 2021 |
| FY2020 | Apr 30, 2018 | $1.36B | Jun 19, 2020 |
| FY2019 | Apr 30, 2017 | $1.38B | Jun 17, 2019 |
| FY2018 | Apr 30, 2016 | $1.51B | Jun 18, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $1.21B | Jun 18, 2025 |
| FY2025 | Apr 30, 2024 | $1.23B | Jun 18, 2025 |
| FY2025 | Apr 30, 2023 | $1.19B | Jun 18, 2025 |
| FY2024 | Apr 30, 2022 | $1.14B | Jun 18, 2024 |
| FY2023 | Apr 30, 2021 | $1.57B | Jun 20, 2023 |
| FY2022 | Apr 30, 2020 | $1.25B | Jun 16, 2022 |
| FY2021 | Apr 30, 2019 | $1.14B | Jun 17, 2021 |
| FY2020 | Apr 30, 2018 | $1.22B | Jun 19, 2020 |
| FY2012 | Apr 30, 2012 | $730.93M | Jun 25, 2012 |
| FY2012 | Apr 30, 2011 | $391.56M | Jun 25, 2012 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $393.80M | Jun 18, 2025 |
| FY2025 | Apr 30, 2024 | $586.50M | Jun 18, 2025 |
| FY2025 | Apr 30, 2023 | $477.40M | Jun 18, 2025 |
| FY2024 | Apr 30, 2022 | $417.50M | Jun 18, 2024 |
| FY2023 | Apr 30, 2021 | $306.70M | Jun 20, 2023 |
| FY2022 | Apr 30, 2020 | $269.30M | Jun 16, 2022 |
| FY2021 | Apr 30, 2019 | $359.80M | Jun 17, 2021 |
| FY2020 | Apr 30, 2018 | $321.90M | Jun 19, 2020 |
| FY2019 | Apr 30, 2017 | $192.40M | Jun 17, 2019 |
| FY2018 | Apr 30, 2016 | $201.40M | Jun 18, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $17.56B | Jun 18, 2025 |
| FY2025 | Apr 30, 2024 | $20.27B | Jun 18, 2025 |
| FY2025 | Apr 30, 2023 | $14.99B | Jun 18, 2025 |
| FY2024 | Apr 30, 2022 | $16.06B | Jun 18, 2024 |
| FY2023 | Apr 30, 2021 | $16.28B | Jun 20, 2023 |
| FY2022 | Apr 30, 2020 | $16.97B | Jun 16, 2022 |
| FY2021 | Apr 30, 2019 | $16.71B | Jun 17, 2021 |
| FY2020 | Apr 30, 2018 | $15.30B | Jun 19, 2020 |
| FY2019 | Apr 30, 2017 | $15.64B | Jun 17, 2019 |
| FY2018 | Apr 30, 2016 | $15.98B | Jun 18, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $11.48B | Jun 18, 2025 |
| FY2025 | Apr 30, 2024 | $12.58B | Jun 18, 2025 |
| FY2024 | Apr 30, 2023 | $7.70B | Jun 18, 2024 |
| FY2023 | Apr 30, 2022 | $7.91B | Jun 20, 2023 |
| FY2022 | Apr 30, 2021 | $8.16B | Jun 16, 2022 |
| FY2021 | Apr 30, 2020 | $8.78B | Jun 17, 2021 |
| FY2020 | Apr 30, 2019 | $8.74B | Jun 19, 2020 |
| FY2019 | Apr 30, 2018 | $7.41B | Jun 17, 2019 |
| FY2018 | Apr 30, 2017 | $8.79B | Jun 18, 2018 |
| FY2017 | Apr 30, 2016 | $8.98B | Jun 19, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $6.08B | Jun 18, 2025 |
| FY2025 | Apr 30, 2024 | $7.69B | Jun 18, 2025 |
| FY2025 | Apr 30, 2023 | $7.29B | Jun 18, 2025 |
| FY2025 | Apr 30, 2022 | $8.14B | Jun 18, 2025 |
| FY2024 | Apr 30, 2021 | $8.12B | Jun 18, 2024 |
| FY2023 | Apr 30, 2020 | $8.19B | Jun 20, 2023 |
| FY2022 | Apr 30, 2019 | $7.97B | Jun 16, 2022 |
| FY2021 | Apr 30, 2018 | $7.89B | Jun 17, 2021 |
| FY2020 | Apr 30, 2017 | $6.85B | Jun 19, 2020 |
| FY2019 | Apr 30, 2016 | $7.01B | Jun 17, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $5.71B | Jun 18, 2025 |
| FY2025 | Apr 30, 2024 | $7.65B | Jun 18, 2025 |
| FY2025 | Apr 30, 2023 | $5.22B | Jun 18, 2025 |
| FY2024 | Apr 30, 2022 | $6.02B | Jun 18, 2024 |
| FY2023 | Apr 30, 2021 | $6.02B | Jun 20, 2023 |
| FY2022 | Apr 30, 2020 | $6.30B | Jun 16, 2022 |
| FY2021 | Apr 30, 2019 | $6.31B | Jun 17, 2021 |
| FY2020 | Apr 30, 2018 | $5.94B | Jun 19, 2020 |
| FY2019 | Apr 30, 2017 | $6.08B | Jun 17, 2019 |
| FY2018 | Apr 30, 2016 | $6.09B | Jun 18, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $501.80M | Jun 18, 2025 |
| FY2025 | Apr 30, 2024 | $2.19B | Jun 18, 2025 |
| FY2024 | Apr 30, 2023 | $2.13B | Jun 18, 2024 |
| FY2023 | Apr 30, 2022 | $2.89B | Jun 20, 2023 |
| FY2022 | Apr 30, 2021 | $2.85B | Jun 16, 2022 |
| FY2021 | Apr 30, 2020 | $2.75B | Jun 17, 2021 |
| FY2020 | Apr 30, 2019 | $2.37B | Jun 19, 2020 |
| FY2019 | Apr 30, 2018 | $2.24B | Jun 17, 2019 |
| FY2018 | Apr 30, 2017 | $1.24B | Jun 18, 2018 |
| FY2017 | Apr 30, 2016 | $1.27B | Jun 19, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Apr 30, 2019 | $101.30M | Jun 17, 2019 |
| FY2019 | Apr 30, 2018 | $192.60M | Jun 17, 2019 |
| FY2019 | Apr 30, 2017 | $166.80M | Jun 17, 2019 |
| FY2019 | Apr 30, 2016 | $109.80M | Jun 17, 2019 |
| FY2018 | Apr 30, 2015 | $125.60M | Jun 18, 2018 |
| FY2017 | Apr 30, 2014 | $153.50M | Jun 19, 2017 |
| FY2016 | Apr 30, 2013 | $256.40M | Jun 21, 2016 |
| FY2015 | Apr 30, 2012 | $229.70M | Jun 25, 2015 |
| FY2014 | Apr 30, 2011 | $319.80M | Jun 23, 2014 |
| FY2013 | Apr 30, 2010 | $283.60M | Jun 21, 2013 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $7.04B | Jun 18, 2025 |
| FY2025 | Apr 30, 2024 | $7.77B | Jun 18, 2025 |
| FY2024 | Apr 30, 2023 | $4.31B | Jun 18, 2024 |
| FY2023 | Apr 30, 2022 | $4.31B | Jun 20, 2023 |
| FY2022 | Apr 30, 2021 | $4.67B | Jun 16, 2022 |
| FY2021 | Apr 30, 2020 | $5.37B | Jun 17, 2021 |
| FY2020 | Apr 30, 2019 | $5.48B | Jun 19, 2020 |
| FY2019 | Apr 30, 2018 | $4.69B | Jun 17, 2019 |
| FY2018 | Apr 30, 2017 | $4.94B | Jun 18, 2018 |
| FY2017 | Apr 30, 2016 | $5.15B | Jun 19, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | (11) | Jun 18, 2025 |
| FY2025 | Apr 30, 2024 | 7 | Jun 18, 2025 |
| FY2025 | Apr 30, 2023 | 0 | Jun 18, 2025 |
| FY2024 | Apr 30, 2022 | 5 | Jun 18, 2024 |
| FY2023 | Apr 30, 2021 | 7 | Jun 20, 2023 |
| FY2020 | Apr 30, 2020 | 1 | Jun 19, 2020 |
| FY2020 | Jan 31, 2020 | 1 | Jun 19, 2020 |
| FY2020 | Oct 31, 2019 | 1 | Jun 19, 2020 |
| FY2020 | Jul 31, 2019 | 1 | Jun 19, 2020 |
| FY2020 | Apr 30, 2019 | 0 | Jun 19, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | (11) | Jun 18, 2025 |
| FY2025 | Apr 30, 2024 | 7 | Jun 18, 2025 |
| FY2025 | Apr 30, 2023 | 0 | Jun 18, 2025 |
| FY2024 | Apr 30, 2022 | 5 | Jun 18, 2024 |
| FY2023 | Apr 30, 2021 | 7 | Jun 20, 2023 |
| FY2020 | Apr 30, 2020 | 1 | Jun 19, 2020 |
| FY2020 | Jan 31, 2020 | 1 | Jun 19, 2020 |
| FY2020 | Oct 31, 2019 | 1 | Jun 19, 2020 |
| FY2020 | Jul 31, 2019 | 1 | Jun 19, 2020 |
| FY2020 | Apr 30, 2019 | 0 | Jun 19, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | 106.43M | Jun 18, 2025 |
| FY2025 | Apr 30, 2024 | 106.19M | Jun 18, 2025 |
| FY2024 | Apr 30, 2023 | 104.40M | Jun 18, 2024 |
| FY2023 | Apr 30, 2022 | 106.46M | Jun 20, 2023 |
| FY2022 | Apr 30, 2021 | 108.34M | Jun 16, 2022 |
| FY2021 | Apr 30, 2020 | 114.07M | Jun 17, 2021 |
| FY2020 | Apr 30, 2019 | 113.74M | Jun 19, 2020 |
| FY2019 | Apr 30, 2018 | 113.57M | Jun 17, 2019 |
| FY2018 | Apr 30, 2017 | 113.44M | Jun 18, 2018 |
| FY2017 | Apr 30, 2016 | 116.31M | Jun 19, 2017 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $455.40M | Jun 18, 2025 |
| FY2025 | Apr 30, 2024 | $437.50M | Jun 18, 2025 |
| FY2025 | Apr 30, 2023 | $430.20M | Jun 18, 2025 |
| FY2024 | Apr 30, 2022 | $418.10M | Jun 18, 2024 |
| FY2023 | Apr 30, 2021 | $403.20M | Jun 20, 2023 |
| FY2022 | Apr 30, 2020 | $396.80M | Jun 16, 2022 |
| FY2021 | Apr 30, 2019 | $377.90M | Jun 17, 2021 |
| FY2020 | Apr 30, 2018 | $350.30M | Jun 19, 2020 |
| FY2019 | Apr 30, 2017 | $339.30M | Jun 17, 2019 |
| FY2018 | Apr 30, 2016 | $316.60M | Jun 18, 2018 |